Full-Time

Director, CMC Product Development

Biologics

Updated on 9/3/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$217k - $226.8k/yr

+ Annual bonus + Long-term incentive award/equity

Boston, MA, USA + 1 more

More locations: Durham, NC, USA

Hybrid

At least two days on-site per week, currently Tuesday and Wednesday; additional on-site days may be required.

PhD

Category
Biology & Biotech (1)
Required Skills
Risk Management

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • A Ph.D. in Pharmaceutical Sciences, Biochemistry, Chemical Engineering, or a closely related discipline, or equivalent work experience.
  • At least 10 years of CMC biologics experience with expertise in drug product formulation and/or fill-finish process development in the pharmaceutical or biotechnology industry.
  • Deep expertise in biologics formulation science, including protein stability, aggregation mitigation, excipient selection, lyophilization cycle development, and container-closure systems.
  • Comprehensive knowledge of ICH Q8, Q9, Q10, and Q11; relevant biologics CMC guidelines Q5A through Q5E; and FDA and EMA drug product development expectations, including experience authoring BLA drug product sections.
  • Experience managing biologics drug product contract development and manufacturing organization relationships, including technical oversight of fill-finish operations, process scale-up, process qualification, and commercial readiness.
  • Experience with lyophilized and liquid formulation development for parenteral biologics, including primary packaging compatibility and extractables and leachables considerations.
  • Working knowledge of biologics drug substance upstream and downstream processes sufficient to partner with Drug Substance teams on interface activities and integrated CMC planning.
  • A track record of operating effectively in pre-commercial, resource-constrained environments while balancing strategic vision with hands-on execution and infrastructure building.
  • Experience managing senior-level cross-functional stakeholder relationships, influencing without authority, and aligning diverse teams around shared program goals.
  • Ability to translate complex CMC biologics science into clear, decision-ready narratives for executive leadership, cross-functional partners, and non-technical stakeholders.
  • Strong written and verbal communication skills, including experience authoring regulatory documents, scientific reports, and executive-level presentations.
  • Ability to establish trust across Research, Clinical, Regulatory, Quality, and external partners in a matrixed organization.
Responsibilities
  • Define and execute the biologics drug product development strategy, including formulation development, fill-finish process development, primary container-closure selection, and applicable device development.
  • Lead formulation development for protein-based therapeutics, including excipient screening, formulation optimization, forced degradation, and compatibility studies.
  • Oversee drug product process development and scale-up, including fill-finish requirements, technology transfer to contract development and manufacturing organization partners, process characterization, and validation readiness.
  • Author and review biologics drug product sections of regulatory submissions, including Investigational New Drug applications, Biologics License Applications, and Type A and Type B meeting packages.
  • Lead or support FDA and EMA interactions on drug product CMC topics.
  • Select and technically govern contract development and manufacturing organization partners responsible for biologics drug product manufacturing, including clinical supply chain coordination, change control oversight, and deviation management.
  • Collaborate with Analytical Development to define drug product release and stability specifications, in-process controls, and comparability strategies for process and formulation changes.
  • Partner with Clinical Operations and Supply Chain to ensure uninterrupted clinical supply across Phase 1 through Phase 3 trials, including labeling, packaging, and cold-chain logistics planning.
  • Integrate Quality by Design principles, Design of Experiments, and risk-management tools into biologics drug product development decisions.
  • Evaluate novel drug delivery technologies and applicable device requirements, including prefilled syringe and autoinjector platforms.
  • Contribute to CMC due diligence assessments and portfolio planning by evaluating the manufacturability and development feasibility of biologic drug product candidates.
  • Perform other duties and responsibilities as assigned.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...